Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 60.~* Patients with a new diagnosis of histologically confirmed (according to WHO classification 2008) acute myeloid leukemia (either primary or secondary AML) are included.~* Patients with a diagnosis of myelodysplastic syndrome with \>/= 10% bone marrow blasts with no response or progression of disease after at least 4 cycles of a hypomethylating agent (5-azacytiine or decitabine).~* Patients must have a healthy blood-related donor (parent, child, sibling) willing to undergo apheresis after G-CSF administration.~* Karnofsky performance status \> 70%.~* Hepatic function - total bilirubin \< 2 and, AST \< 2.5 x upper limit of normal, unless liver is involved with disease or a history of Gilbert's disease.~* Renal function - adequate renal function as demonstrated by a serum creatinine \<2 mg/dl.~* LVEF ≥ 50% as determined by echocardiogram or MUGA.~* Ability to give informed consent.~Donor Eligibility:~* Donor is blood-related and HLA-haploidentical to the recipient.~* Donor ≥18 years old~* Donor has undergone serologic testing for transmissible diseases as per blood banking guidelines for organ and tissue donors. Tests include but are not limited to: HepBsAg, HepBsAb, HepBcAb, HepC antibody, HIV, HTLV I and II, VZV, CMV and VDRL, and West Nile Virus . Donor must have normal negative test results for HIV, HTLV I and II, and West Nile Virus.~* Donor has a CXR and EKG performed.~* Donor is not allergic to G-CSF.~* Donor must be able to undergo leukapheresis~* Donor is not pregnant.~* Donor does not have concurrent malignancy or autoimmune disease.~* Ability to give informed consent.~Exclusion Criteria:~* Patients with a diagnosis of acute promyelocytic leukemia (according to WHO classification 20080~* Major surgery or irradiation within two weeks.~* Previous therapy with cytotoxic agents for AML. Persons with previous treatments for myelodysplasia/myeloproliferation such as hydroxyurea, interferon, hypomethylating agents (5-azacitidine or decitabine), lenalidomide, or JAK/STAT inhibitors may participate but must have \>1 week off therapy prior to enrollment.~* Active CNS disease.~* Uncontrolled infection.~* Pregnant or lactating women - they are excluded, given the potential teratogenic effects of chemotherapy and agents used in the therapy.~* Male and female patients of child-bearing potential unwilling to use effective means of contraception.~* HIV or HTLV I/II seropositivity.~* Concurrent active malignancy other than AML requiring therapy.~* Clinically significant cardiac disease (NY Heart Association Class III or IV) or pulmonary disease.~* Inability or unwillingness to comply with the treatment protocol, follow-up, or research tests~Donor Exclusion:~* Donor has cardiac risk factors precluding ability to undergo leukapheresis.~* Donor has evidence of concurrent malignancy or autoimmune disease.~* Donor is pregnant

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells (Type: EXPERIMENTAL): This is a single center trial to assess the feasibility of standard induction chemotherapy followed by a single dose of unmanipulated G-PBSC for the treatment of elderly patients with newly diagnosed AML.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues